Diabetic kidney disease (DKD) is a common and serious complication of diabetes. It's the leading cause of end-stage kidney disease requiring dialysis or transplant.
The scary part? Kidney damage can be silent for years. You may not notice symptoms until significant damage has occurred.
The good news: with early detection and proper treatment, diabetic kidney disease can often be slowed or prevented. The 2025 ADA guidelines provide a clear roadmap for protecting your kidneys.
| Process | Effect |
|---|
| High blood glucose | Damages filtering units (glomeruli) |
| High blood pressure | Increases pressure in kidney filters |
| Inflammation | Causes scarring of kidney tissue |
| Fibrosis | Progressive loss of functional tissue |
| Albumin leakage | Protein spills into urine |
| Statistic | Impact |
|---|
| 20-40% of people with diabetes develop DKD | |
| #1 cause of ESRD in the US | |
| Increases mortality 2-3x compared to diabetes without DKD | |
| Silent progression until advanced stages | |
| Patient Group | When to Start |
|---|
| Type 1 diabetes | 5 years after diagnosis |
| Type 2 diabetes | At diagnosis |
| Both types | Annually thereafter |
| Test | What It Measures | Target |
|---|
| eGFR | Estimated glomerular filtration rate | ≥ 60 mL/min/1.73 m² |
| UACR | Urine albumin-to-creatinine ratio | < 30 mg/g |
eGFR (Kidney Function)
| Category | eGFR (mL/min/1.73 m²) | Meaning |
|---|
| G1 | ≥ 90 | Normal or high |
| G2 | 60-89 | Mildly decreased |
| G3a | 45-59 | Mild-moderate decrease |
| G3b | 30-44 | Moderate-severe decrease |
| G4 | 15-29 | Severely decreased |
| G5 | < 15 | Kidney failure |
UACR (Albumin in Urine)
| Category | UACR (mg/g) | Meaning |
|---|
| A1 | < 30 | Normal to mildly increased |
| A2 | 30-300 | Moderately increased (microalbuminuria) |
| A3 | > 300 | Severely increased (macroalbuminuria) |
| Stage | eGFR | Albuminuria | Risk |
|---|
| Stage 1 | ≥ 90 | A1-A3 | Low-moderate |
| Stage 2 | 60-89 | A1-A3 | Low-moderate |
| Stage 3a | 45-59 | A1-A3 | Moderate-high |
| Stage 3b | 30-44 | A1-A3 | High |
| Stage 4 | 15-29 | A1-A3 | Very high |
| Stage 5 | < 15 | A1-A3 | Very high |
| Target | Benefit |
|---|
| A1C < 7.0% (individualized) | Slows DKD progression by 30-50% |
| Early control | Greatest benefit before significant damage |
| Avoid hypoglycemia | Especially in advanced CKD |
Note: Once advanced CKD develops, A1C targets may be relaxed to avoid hypoglycemia.
| Target | Population |
|---|
| <130/80 mmHg | Most patients with diabetes + albuminuria |
| <140/90 mmHg | Older adults or frail patients |
First-Line Medications
| Medication Class | Kidney Benefit | Notes |
|---|
| ACE inhibitors | Slows DKD progression | First choice |
| ARBs | Slows DKD progression | Alternative if ACE not tolerated |
| Combination | NOT recommended | Increases risk |
Key point: Most people with diabetes + albuminuria should be on an ACE inhibitor or ARB regardless of blood pressure.
| Medication | Kidney Benefit | When to Use |
|---|
| Canagliflozin | Slows eGFR decline, reduces ESRD | eGFR ≥ 20 |
| Dapagliflozin | Slows eGFR decline, reduces ESRD | eGFR ≥ 25 |
| Empagliflozin | Cardio-renal benefit | eGFR ≥ 20 |
| Ertugliflozin | Similar benefits | eGFR ≥ 30 |
Evidence: CREDENCE, DAPA-CKD, and EMPA-KIDNEY trials showed SGLT2 inhibitors slow DKD progression by 30-40%.
| Medication | Benefit | When to Use |
|---|
| Finerenone | Reduces albuminuria, slows eGFR decline | Type 2 diabetes + CKD (eGFR 25-90) |
Note: Monitor potassium levels when using finerenone.
| Benefit | Evidence |
|---|
| Reduced albuminuria | Consistent across agents |
| Slowed eGFR decline | Some agents |
| Cardiovascular benefit | Proven for several agents |
| Patient Category | Recommended Protein Intake |
|---|
| DKD stages 1-4 | 0.8 g/kg body weight/day |
| Dialysis | 1.0-1.2 g/kg body weight/day |
Note: High protein intake may increase kidney hyperfiltration and accelerate damage.
| Target | Benefit |
|---|
| <2,000 mg/day | Lowers blood pressure, reduces albuminuria |
| Ideal < 1,500 mg/day | Greater benefit |
| Nutrient | Consideration |
|---|
| Potassium | May need restriction in advanced CKD |
| Phosphorus | May need restriction in advanced CKD |
| Processed foods | Limit (high sodium and phosphorus) |
| Situation | Action |
|---|
| eGFR < 30 | Refer to nephrology |
| Rapid eGFR decline (> 5 mL/min/year) | Refer to nephrology |
| Difficult-to-control BP | Refer to nephrology |
| Albuminuria > 300 mg/g | Refer to nephrology |
| Uncertainty about cause | Refer to nephrology |
| Planning for renal replacement | Refer to nephrology |
| Complication | Monitoring/Management |
|---|
| Anemia | Check hemoglobin, consider ESA |
| Bone mineral disease | Check calcium, phosphorus, PTH |
| Hyperkalemia | Monitor potassium, restrict if needed |
| Metabolic acidosis | Check bicarbonate |
| Fluid overload | May need diuretics |
| Indication | Threshold |
|---|
| eGFR | < 15 mL/min/1.73 m² |
| Symptoms | Uremic symptoms, fluid overload, electrolyte abnormalities |
| Preparation | Start planning at eGFR < 20-25 |
| Option | Description |
|---|
| Hemodialysis | In-center, 3x weekly |
| Peritoneal dialysis | Home-based, daily |
| Kidney transplant | Best outcomes if suitable candidate |
| Situation | Management |
|---|
| Pre-existing DKD | High-risk pregnancy, close monitoring |
| ACE inhibitors/ARBs | Contraindicated in pregnancy |
| SGLT2 inhibitors | Discontinue before pregnancy |
| Pregnancy planning | Preconception counseling essential |
- Annual screening for DKD is essential for all people with diabetes
- Type 2: screen at diagnosis; Type 1: screen 5 years after diagnosis
- Two tests needed: eGFR (kidney function) and UACR (albumin in urine)
- ACE inhibitors or ARBs are first-line for diabetes + albuminuria
- SGLT2 inhibitors provide additional kidney protection
- Blood pressure target: < 130/80 mmHg for most patients
- Refer to nephrology when eGFR < 30 or rapid decline
Early diabetic kidney disease typically has NO symptoms. As kidney function declines, you may notice swelling in legs/feet/eyes, increased fatigue, foamy urine, or needing to urinate more at night. This is why annual screening with blood and urine tests is essential—don't wait for symptoms.
An eGFR below 30 mL/min/1.73 m² generally warrants referral to a nephrologist (kidney specialist). Earlier referral may be appropriate if there's rapid decline in kidney function, difficult-to-control blood pressure, or uncertainty about the cause of kidney disease.
Once significant kidney damage has occurred, it generally cannot be reversed. However, progression can often be slowed or even halted with proper management including tight glycemic control, blood pressure control, and kidney-protective medications (ACE inhibitors/ARBs, SGLT2 inhibitors).
With diabetic kidney disease, limit high-sodium foods (< 2,000 mg/day), limit protein to 0.8 g/kg/day (unless on dialysis), and in advanced stages, limit potassium and phosphorus. Avoid processed foods, which are often high in sodium and phosphorus additives. Work with a renal dietitian for personalized guidance.
Not all, but SGLT2 inhibitors are recommended for most people with type 2 diabetes and chronic kidney disease (eGFR ≥ 20-25 depending on the specific medication) because of their proven kidney and cardiovascular benefits. The decision should be individualized based on eGFR, cardiovascular risk, and other factors.
Sources:
- American Diabetes Association. Standards of Care in Diabetes—2025. Diabetes Care 2025; 48(Suppl 1): S211-S225 (Section 16: Kidney Disease)
- KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about your health, treatment, or care. Individual circumstances vary, and what is appropriate for one person may not be appropriate for another.
If you are experiencing a medical emergency, call 911 (or your local emergency number) immediately.